An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background IMM-101 is a heat-killed innate and adaptive immune-activating mycobacterial product; a phase I study aimed to determine its safety and tolerability in individuals with melanoma.Patients and methods An intra-patient placebo-controlled study evaluated the safety and tolerability of three doses, namely, 0.1 (1 mg/ml), 0.5 (5 mg/ml) and 1.0 mg (10 mg/ml) of IMM-101 in stage III or IV melanoma. Each dose was administered in ascending order to one of the three cohorts.Results Based on observations from patients administered the 0.1-mg dose, it was considered appropriate to proceed with dosing the patients in the 0.5-mg dose cohort and then the 1.0-mg cohort (n = 6 per cohort). Treatment-emergent adverse events that would be considered typical of a post-vaccination state (including joint pains/aches, headaches and influenza-like symptoms) occurred at all dose levels, along with injection site reactions. These were mainly mild in intensity, resolved in a matter of days and responded well to supportive care. During post-study follow-up, two clinical responses (15%) were observed in patients with stage IV disease.Conclusion IMM-101 is safe and well tolerated and there is a rationale for studying IMM-101 at a nominal 1.0-mg dose to complement conventional cytotoxic therapy for patients with advanced cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, it has been observed that the intradermal injection of Mycobacterium obuense in melanoma and in pancreatic ductal carcinoma activates antitumoral immune response, acting on host’s antigen presenting cells (APCs) and cytotoxic T cells [159,160].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [159]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
Management of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 855
Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Rigel, D. S. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.10.005 · Cited by 159
Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells
Yvon, E., Del Vecchio, M., Savoldo, B., Hoyos, V., Dutour, A., Anichini, A., Dotti, G., & Brenner, M. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3163 · Cited by 141
Quintarelli, C., Dotti, G., Hasan, S. T., Angelis, B. D., Hoyos, V., Errichiello, S., Mims, M. P., Luciano, L., Shafer, J. A., Leen, A. M., et al. (2011) · Blood · doi:10.1182/blood-2010-08-300376 · Cited by 96
Pfahlberg, A. B., Schneider, D. I., Uter, W. J. C., Gefeller, O., Kölmel, K. F., Grange, J. M., Mastrangelo, G., Krone, B., Botev, I. N., Niin, M., et al. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.00643.x · Cited by 93
Self-citationPennock, G. K., Waterfield, W., & Wolchok, J. D. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318209cda9 · Cited by 84 · cited 1×
“Symptoms related to autoimmunity develop in some patients since host defences subjected to checkpoint blockade lose the ability to discriminate between self and nonself [13, 14].”
BackgroundSuccessful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung
Stanford, J. L., Stanford, C. A., O'Brien, M. E. R., & Grange, J. M. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.021 · Cited by 68
Self-citationMaraveyas, A., Baban, B., Kennard, D., Rook, G. A. W., Westby, M., Grange, J. M., Lydyard, P. M., Stanford, J. L., Jones, M., Selby, P., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008307821189 · Cited by 66
Self-citationTargeting the Immune System in Cancer
Chaudhuri, D., Suriano, R., Mittelman, A., & Tiwari, R. K. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109787315114 · Cited by 61
Tuberculosis and cancer: parallels in host responses and therapeutic approaches?
Grange, J. M., Stanford, J. L., & Rook, G. A. W. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92542-2 · Cited by 56
Self-citationThe use of mycobacterial adjuvant-based agents for immunotherapy of cancer
Grange, J. M., Bottasso, O. A., Stanford, C. A., & Stanford, J. L. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.092 · Cited by 55
Self-citationTreating Cancer by Targeting the Immune System
Hwu, P. (2010) · New England Journal of Medicine · doi:10.1056/nejme1006416 · Cited by 49
Weber, J. S. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283436e79 · Cited by 47
Lahey, T., Arbeit, R. D., Bakari, M., Horsburgh, C. R., Matee, M. I., Waddell, R. D., Mtei, L., Vuola, J. M., Pallangyo, K., & von Reyn, C. F. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.09.041 · Cited by 45
Campbell De Morgan's 'Observations on cancer', and their relevance today
Grange, J. M., Stanford, J. L., & Stanford, C. A. (2002) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.95.6.296 · Cited by 43
Self-citationPatel, P. M., Sim, S., O’Donnell, D., Protheroe, A. S., Beirne, D., Stanley, A. J., Tourani, J. M., Khayat, D., Hancock, B. W., Vasey, P. A., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.11.003 · Cited by 43
Self-citationIpilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
Peggs, K. S., & Quezada, S. A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.144 · Cited by 39
Stanford, J. L., Stanford, C. A., Grange, J. M., LAN, N. N., & Etemadi, A. (2001) · Respiratory Medicine · doi:10.1053/rmed.2001.1065 · Cited by 36
Self-citationLe Bert, N., Chain, B. M., Rook, G., & Noursadeghi, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018346 · Cited by 34 · cited 1×
“Mycobacterium vaccae, which is closely related to the mycobacterial preparation used here, is recognised by toll-like receptor 2 (TLR2), but in contrast to other TLRs ligands, it induces specific maturation of monocyte-derived dendritic cells (DCs), which when placed in culture with naive CD4+ T cells is associated wi…”
BackgroundAdvances in targeted therapy for melanoma.
Friedlander, P. A., & Hodi, F. S. (2010) · PubMed · Cited by 27
Yang, H., Hu, B., Xiao, L., & Wang, P. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.13 · Cited by 24
The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Stanford, J. L., Stanford, C. A., Stansby, G. P., Bottasso, O. A., Bahr, G. M., & Grange, J. M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787846838 · Cited by 21
Self-citationImmunologic functions as prognostic indicators in melanoma
Bouwhuis, M. G., ten Hagen, T. L. M., & Eggermont, A. M. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.01.004 · Cited by 21 · cited 1×
“There are a number of ways, in principle, whereby the power of the immune system can be harnessed to treat cancer [1, 2].”
BackgroundImmunotherapy for malignant melanoma – Tracing Ariadne’s thread through the labyrinth
Grange, J. M., Krone, B., & Stanford, J. L. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.002 · Cited by 18
Self-citationRestoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases
Wilgenhof, S., Pierret, L., Corthals, J., Nuffel, A. M. T. V., Heirman, C., Roelandt, T., Coninck, A. L. D., Verfaillie, G., Vandenbroucke, F., Riet, I. V., et al. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e328343ece0 · Cited by 11 · cited 1×
“Symptoms related to autoimmunity develop in some patients since host defences subjected to checkpoint blockade lose the ability to discriminate between self and nonself [13, 14].”
BackgroundGRANGE, J. M., & Stanford, J. L. (1996) · Journal of Medical Microbiology · doi:10.1099/00222615-45-2-81 · Cited by 6
Self-citationStebbing, J., Wood, C. G., Atkins, M. B., Bukowski, R. M., Litwin, S., Bower, M., Parsa, A. T., & Levitsky, H. I. (2008) · Cancer · doi:10.1002/cncr.23273 · Cited by 5 · cited 1×
“There are a number of ways, in principle, whereby the power of the immune system can be harnessed to treat cancer [1, 2].”
BackgroundSelf-citationGrange, J. M., Doré, J., & Coebergh, J. W. W. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.09.024 · Cited by 3
Self-citationPreventing relapse in melanoma
Stebbing, J., & Gore, M. E. (2000) · Current Oncology Reports · doi:10.1007/s11912-000-0068-y · Cited by 2 · cited 1×
“Enrolment in a clinical trial has become the standard of care for both earlyand late-stage disease [7, 8].”
BackgroundSelf-citation
Cited by
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G. L., Tonini, G., & Libra, M. (2019) · Cancers · doi:10.3390/cancers11010038 · Cited by 586
“ductal carcinoma activates antitumoral immune response, acting on host’s antigen presenting cells (APCs) and cytotoxic T cells [159,160].”
BackgroundAnticancer effects of the microbiome and its products
Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.44 · Cited by 538
Combinations of Immunotherapy and Radiation in Cancer Therapy
Vatner, R. E., Cooper, B. T., Vanpouille-Box, C., Demaria, S., & Formenti, S. C. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00325 · Cited by 240
“A suspension of heat killed Mycobacterium obuense, called IMM–101, also contains TLR2 agonists, which has been shown to be safe and well tolerated in human beings (122).”
BackgroundTrial Watch: Experimental Toll-like receptor agonists for cancer therapy
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20696 · Cited by 195
Metadata
- Authors
- Stebbing, J., Dalgleish, A., Gifford-Moore, A., Martin, A., Gleeson, C., Wilson, G., Brunet, L. R., Grange, J., & Mudan, S.
- Affiliations
- Imperial College Healthcare NHS Trust (GB)
- St George's, University of London (GB)
- Immodulon Therapeutics (United Kingdom) (GB)
- Corresponding author
- Stebbing, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 23
- Issue
- 5
- Pages
- 1314-1319
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2119076281
- Cited by
- 55
- References
- 35
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2761 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Cancer Research UK (14549)
- National Institute for Health and Care Research (NIHR-RP-011-053)
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- melanoma, heat-killed mycobacteria, intradermal administration, safety and tolerability, treatment-emergent adverse events, stage IV melanoma, immune activation, cancer immunotherapy
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Bacterial Vaccines, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Immunotherapy, Injections, Intradermal, Male, Melanoma, Middle Aged, Models, Biological, Mycobacterium, Placebos, Skin Neoplasms, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.